Charlotte Knights

7.4k total citations · 1 hit paper
13 papers, 5.4k citations indexed

About

Charlotte Knights is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Charlotte Knights has authored 13 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Oncology and 3 papers in Genetics. Recurrent topics in Charlotte Knights's work include PARP inhibition in cancer therapy (10 papers), DNA Repair Mechanisms (9 papers) and BRCA gene mutations in cancer (3 papers). Charlotte Knights is often cited by papers focused on PARP inhibition in cancer therapy (10 papers), DNA Repair Mechanisms (9 papers) and BRCA gene mutations in cancer (3 papers). Charlotte Knights collaborates with scholars based in United Kingdom, South Korea and China. Charlotte Knights's co-authors include Niall M.B. Martin, Graeme C.M. Smith, Hannah Farmer, Christopher J. Lord, Andrew Tutt, Ian Hickson, Alan Ashworth, Nuala McCabe, Manuela Santarosa and Stephen P. Jackson and has published in prestigious journals such as Nature, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Charlotte Knights

12 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

2005 4.8k citations Hannah Farmer, Nuala McCabe et al. Nature profile →

Peers

Countries citing papers authored by Charlotte Knights

Since Specialization

Citations

This map shows the geographic impact of Charlotte Knights's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlotte Knights with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlotte Knights more than expected).

Fields of papers citing papers by Charlotte Knights

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlotte Knights. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlotte Knights. The network helps show where Charlotte Knights may publish in the future.

Co-authorship network of co-authors of Charlotte Knights

This figure shows the co-authorship network connecting the top 25 collaborators of Charlotte Knights. A scholar is included among the top collaborators of Charlotte Knights based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlotte Knights. Charlotte Knights is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models 2016 ·Cancer Research ·Lenka Oplustil O’Connor, Stuart L. Rulten, Aaron Cranston, Rajesh Odedra, H. Shelton Brown, Janneke E. Jaspers, (unknown), Charlotte Knights, Bastiaan Evers, Attilla Ting, Robert H. Bradbury, Marina Pajic, Sven Rottenberg, Jos Jonkers, (unknown), Niall M.B. Martin, Keith W. Caldecott, Alan Lau, Mark J. O’Connor	60
2	Abstract 1728: Discovery of highly selective DUB inhibitors with in vivo pre-clinical anti-tumor activity 2015 ·Cancer Research ·Xavier Jacq, Niall M.B. Martin, Lisa M. Smith, Jeanine A. Harrigan, Charlotte Knights, Helen M.R. Robinson, Yaara Ofir-Rosenfeld, Aaron Cranston, Mark I. Kemp, Stephen P. Jackson	1
3	Abstract 3497: Identifying pre-clinical predictive biomarkers for the PARP inhibitor olaparib 2010 ·Cancer Research ·Jonathan R. Dry, Alan Lau, Charlotte Knights, Chris Harbron, John E. Prime, Lucy C. Riches, (unknown), Tim Avis, Helen Brown, Sarah Runswick, Simon Dearden, Aisling O'Shaughnessy, Louise Unwin, Tim French, Darren Hodgson, Mark J. O’Connor	1
4	Abstract 1775: Growth inhibitory effect of PARP inhibitor olaparib in gastric cancer cells 2010 ·Cancer Research ·Seock‐Ah Im, Ahrum Min, Hyung-Seok Hur, Young‐Kwang Yoon, Sang Hyun Song, Lucy C. Riches, Charlotte Knights, Sae‐Won Han, Do‐Youn Oh, (unknown), Tae‐You Kim, Yi Gu, Alan Lau, Yung‐Jue Bang, Mark J. O’Connor	1
5	DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype 2010 ·Journal of Medicinal Chemistry ·Céline Cano, Olivier Barbeau, C. L. Bailey, Xiaoling Cockcroft, Nicola J. Curtin, (unknown), Mark Frigerio, Bernard T. Golding, Ian R. Hardcastle, Marc Hummersone, Charlotte Knights, Keith Menear, David R. Newell, Caroline J. Richardson, Graeme C. M. Smith, (unknown), Roger J. Griffin	35
6	Abstract #5494: Pre-clinical evaluation of single-agent activity of the PARP inhibitor olaparib (AZD2281) in homologous recombination deficient triple-negative breast cancer 2009 ·Cancer Research ·Charlotte Knights, Lucy C. Riches, Alan Lau, (unknown), Tim Avis, Richard S. Finn, Aisling O'Shaughnessy, Aaron Cranston, Ondrej Kalous, Dylan Conklin, James Carmichael, Dennis J. Slamon, Mark J. O’Connor	1
7	Abstract A114: Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer 2009 ·Molecular Cancer Therapeutics ·Charlotte Knights, Christine M. Chresta, Lucy C. Riches, (unknown), Tim Avis, Aisling O'Shaughnessy, Louise Unwin, (unknown), (unknown), Aaron Cranston, J. Carmichael, Niall M.B. Martin, Mark J. O’Connor, Alan Lau	5
8	Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents. 2009 ·Cancer Research ·RS Finn, Alexander Yuk Lun Lau, Ondrej Kalous, Douglas S. Conklin, Judy Dering, Charlotte Knights, Aisling O'Shaughnessy, Aaron Cranston, Lucy C. Riches, J. Carmichael, (unknown), DJ Slamon	5
9	Abstract B42: ATM deficiency sensitizes gastric cancer cells to the PARP inhibitior olaparib 2009 ·Molecular Cancer Therapeutics ·Xiaoning Guo, (unknown), (unknown), Yu Bai, (unknown), Danping Shen, Shirong Zhang, Liang Xie, Charlotte Knights, Alan Lau, Mark J. O’Connor, Xiaolu Yin, Anthony Warford, Yi Gu	9
10	4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1 2008 ·Journal of Medicinal Chemistry ·Keith Menear, (unknown), (unknown), Xiaoling Cockcroft, (unknown), Aaron Cranston, (unknown), (unknown), (unknown), Sylvie Gomez, (unknown), Frank Kerrigan, Charlotte Knights, Alan Lau, (unknown), Ian T.W. Matthews, Stephen Moore, Mark J. O’Connor, Graeme C.M. Smith, Niall M.B. Martin	483
11	557 POSTER Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer 2008 ·European Journal of Cancer Supplements ·(unknown), Alan Lau, (unknown), Charlotte Knights, Aisling O'Shaughnessy, Ondrej Kalous, Dylan Conklin, Lucy C. Riches, J. Carmichael, Dennis J. Slamon	1
12	Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy breakdown → 2005 ·Nature ·Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew Tutt, Damian A. Johnson, (unknown), Manuela Santarosa, (unknown), Ian Hickson, Charlotte Knights, Niall M.B. Martin, Stephen P. Jackson, Graeme C.M. Smith, Alan Ashworth	4751
13	Neutralization and Lipoprotein Binding of Lipopolysaccharides in Tolerant Rabbit Serum 1986 ·The Journal of Infectious Diseases ·H. Shaw Warren, Charlotte Knights, George R. Siber	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact